Adding to comments on the recent criticism of the UK's National Institute for Health and Clinical Excellence (NICE), which gives guidance on the use of medicines in England and Wales (Marketletter January 21), Subhanu Saxena, chief executive of Novartis UK, said that long delays for new compounds to gain approval from the Medicines and Healthcare products Regulatory Agency (MHRA), the regulator, and from the NICE, "are making Britain uncompetitive for drug companies."
In an interview with the Daily Telegraph newspaper, he said "it is becoming expensive to do trials in the UK and hard to launch new drugs," as a results of which "there is a real possibility that drug companies will stop launching drugs in Britain."
According to Mr Saxena, what has become known as "NICE blight," has delayed two of the firm's recent launches in the UK. However, Novartis' head of pharmaceuticals in Europe, Eric Cornut, told the Telegraph that, despite these setbacks, the firm will continue to work with the NICE to introduce its products in Britain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze